970328

BIENNIAL REPORT OF EXAMINING AND LICENSING BOARDS

(M.S. - 1987 Supplement, Section 214.07)

BOARD: MINNESOTA BOARD OF PHARMACY

LOCATION: 2829 University Ave. SE #530, Minneapolis, MN 55414

STATUTORY AUTHORITY: Minnesota Statute 151

REPORTING PERIOD: July 1, 1994 to June 30, 1996

SUBMITTED BY: David E. Holmstrom, Executive Director

DATE: March 31, 1997

Distribution:
1 copy to Secretary of Senate
1 copy to Clerk of the House
6 copies to Legislative Reference Library
1 copy to the Governor
1 copy to the Commissioner of the Department of Health

Clause A: **GENERAL STATEMENT OF BOARD ACTIVITIES**

The function of the Minnesota Board of Pharmacy is to protect the public from adulterated, misbranded, and illicit drugs and to provide the public reasonable assurance of professional competency in the practice of the pharmacy profession through the enforcement of the provisions of the Pharmacy Practice Act, the State Controlled Substances Act, and miscellaneous other acts. Such enforcement involves drug control through testing, licensing, inspecting, and investigating 5,106 pharmacists, 487 pharmacist-interns, 1,227 pharmacies, 567 drug wholesalers, 252 drug manufacturers, 80 drug researchers, and 27 medical gas distributors; through the providing of technical assistance, training and consultation to other health professionals; and through the development of rules and regulations governing storage, distribution, and recordkeeping by persons, institutions, and facilities.

This general function of the Board can essentially be broken down into nine different activities:

(1) Licensing of Pharmacists. Candidates for licensure as pharmacists are examined by Board members in a combination of five professional fields. In addition, a practical examination involving the compounding and dispensing of prescriptions is prepared and administered by the Board members.

Candidates for licensure by reciprocity are cleared through the National Association of Boards of Pharmacy for evidence of proper educational and experience credentials as well as for compliance with pharmacy laws. Only the state exam in pharmaceutical jurisprudence is required of candidates for licensure by reciprocity.

Twice yearly survey/inspections review compliance with: required professional staffing standards, internship training and practice, standards of drug storage and drug quality, minimum equipment, prepackaging activities, bulk compounding, compounding and dispensing, consultation under Medicare requirements, recordkeeping, labeling, security, and miscellaneous practice requirements. In the case of pharmacists in institutional practice, special emphasis is given to the overall drug distribution systems utilized and recognition is given to special compounding and dispensing practices unique to the institutional practice setting.

Beginning with the March 4, 1975 licensing renewal, all pharmacists currently licensed in Minnesota are required to show evidence of having obtained thirty hours of continuing pharmaceutical education every two years in order to maintain their license. Programs from various local, state, and national sponsors must be reviewed and approved for use in meeting the continuing educational requirement. Biennially reports of continuing education attendance and participation must be reviewed and recorded prior to approving the annual registration for pharmacists.

(2) Pharmacy Licensure. Licenses are issued for each pharmacy, community and institutional, in the name of a designated pharmacist-in-charge who must demonstrate that required professional staffing, access, space, security, and equipment standards are met. Each pharmacy is inspected at least annually for compliance with applicable laws and regulations.

(3) Licensure of Drug Wholesalers. All firms handling drugs on a wholesale basis in Minnesota or who are doing business in Minnesota are required to be licensed by the Board. These firms must demonstrate adequate security, temperature and humidity control, sanitation, recordkeeping, and distribution practices at the time of licensing.

Inspection of drug wholesalers are accomplished approximately annually. Attention is given to storage and security capabilities of the firm. Distribution patterns are carefully reviewed to ensure that drugs are sold only to persons legally permitted to possess them. Sanitation is carefully surveyed and environmental control is reviewed.

(4) Licensure of Drug Manufacturers. All firms engaging in the manufacturing, repackaging, or relabeling of drugs are required to be licensed by the Board. At the time of licensure, all firms are required to demonstrate qualification of responsible personnel, records of compliance with drug laws, and equipment and procedures necessary to comply with the good manufacturing procedures of the Food and Drug Administration.

Comprehensive inspections of in-state drug manufacturers are accomplished by the Board's staff on approximately an annual basis. Special attention is given to: source and quality of raw materials; adequacy of building facilities, sanitation, and equipment; design and utilization of master formulas and batch records; manufacturing processes and techniques; in-process security and controls for controlled substances; content and security of labels; packaging control procedures and records; laboratory controls and records; and patterns of distribution of the manufactured product.

(5) Registration of Pharmacist-Interns. Pharmacy students may register as a pharmacist-intern at the end of the third year of the standard five or six year college of pharmacy curricula. Objectives of the internship training program and instructions for performance of pharmacy intern functions and reporting of practical learning experiences are furnished to the interns. Quarterly reports are required of each pharmacy student engaged in the pharmacist-intern practice. Experience as a pharmacist-intern may be obtained in the last two years of the college curriculum and must be commensurate with the interns educational level. Quality of experience is monitored and disciplinary actions taken against pharmacist preceptors or interns who violate internship regulations.

Interns are required to take an internship competency examination prepared by the Board's staff during and at the completion of their internship experience. The examinations are analyzed to show the intern the competency areas in which he/she should strive to gain more experience.

(6) Controlled Substances Regulation. All controlled substances (formerly designated as narcotics or stimulants and depressants) are categorized in M.S. 152 into "Schedules" based on abuse potential. Rescheduling of controlled substances or addition of such substances to one of the existing schedules is accomplished by Board Rule 6800.4200 through 6800.4250. The Board may consult an advisory council on controlled substances on rescheduling proposals and in the consideration of control of newly discovered substances with abuse potential. The Board prescribes recordkeeping requirements for persons authorized to possess controlled substances and will, together with its advisory council, report to the legislature concerning implementation of the Controlled Substances Act and possible amendments to it. This general activity will be perpetual as long as the need for control of such substances with abuse potential exists.

Federal and state drug control activities are coordinated by the Board in a formal agreement with the Federal Drug Enforcement Administration and State Bureau of Criminal Apprehension. This coordination ensures DEA and BCA involvement in "street type" enforcement work and Board of Pharmacy involvement in cases involving illicit drug distribution from any of the various licensed health professionals.

(7) Miscellaneous Drug Control Activities. Investigation of registrants and non-registrants alike for compliance with miscellaneous laws relating to drugs and the provision of special investigative services to other state agencies in the health care and law enforcement areas are involved in Board activities. Other areas of Board activities include:

On-site inspection of distressed drugs which have been subjected to fire, flood, etc., is accomplished by Board staff. Drugs are inspected for evidence of misbranding or adulteration and are embargoed and destroyed if evidence of adulteration or misbranding is present. Similar inspections of distressed drugs which are imported into the state by various salvage companies are performed.

Careless distribution of drug samples is investigated to ensure that all drugs within the state will be distributed legally and safely.

Cases of illegal distribution or possession of hypodermic syringes and needles are investigated.

Compliance with the State Toxic Glue Law is achieved in part by the monitoring of compliance by our licensees.

Special investigations are performed in cooperation with or after requests of other state agencies such as the Department of Health, the Board of Medical Examiners, the Board of Dental Examiners, the Board of Nursing, and the Attorney General.

(8) Registration of Drug Researchers. All individuals seeking to utilize controlled substance drugs in research activities are required to obtain both a state and a federal registration in order to purchase, possess and use these drugs. State registration is carried out through the Board of Pharmacy office and information on these registrants is shared with the federal Drug Enforcement Administration.

(9) Registration of Medical Gas Distributors. Beginning in Fiscal Year 1990, the Board began the registration of those companies engaged in the distribution of prescription medical gases. Certain gaseous substances used for medical purposes are considered "drugs" by FDA. Further, these drugs require a prescriptions for their use. Because of the physical characteristics of gasses, however, they are not dispensed by pharmacies as are other prescription drugs. The Board recently began registering those companies distributing prescription medical gasses to patients and, with the cooperation of FDA, began inspecting these places.

Clause B: **TOTAL NUMBER MEETINGS HELD FY 95 IS 46 MEETINGS, FY 96 IS 55 MEETINGS, FY 95 & 96 IS 10 MEETINGS**

APPROXIMATE TOTAL NUMBER OF HOURS SPENT BY BOARD MEMBERS IN MEETINGS AND ON OTHER BOARD ACTIVITIES.

BOARD MEMBER'S NAME	TYPE	FY 95	FY 96	FY 95 & 96
Denise Frank	Board Meeting	56.0	63.0	119.0
	Committees	7.0	29.0	36.0
	Other Meetings	62.0	64.0	126.0
	Disciplinaries	0.0	6.0	6.0
	Examination	40.0	48.0	88.0
	Grading	11.0	11.0	22.0
Carol Peterson	Board Meeting	56.0	63.0	119.0
	Committees	3.0	9.0	12.0
	Other Meetings	58.0	58.0	116.0
	Disciplinaries	10.0	2.0	12.0
	Examination	48.0	48.0	96.0
	Grading	11.0	11.0	22.0
Wendy Simenson	Board Meeting	56.0	0.0	56.0
	Committees	8.0	14.0	22.0
	Other Meetings	58.0	18.0	76.0
	Disciplinaries	4.0	2.0	6.0
	Examination	48.0	8.0	56.0
	Grading	11.0	1.0	12.0
Howard Juni	Board Meeting	56.0	21.0	77.0
	Committees	6.0	4.0	10.0
	Other Meetings	61.0	21.0	82.0
	Disciplinaries	4.0	0.0	4.0
	Examination	40.0	8.0	48.0
	Grading	11.0	1.0	12.0
Donald Gibson	Board Meeting	56.0	56.0	112.0
	Committees	2.0	2.0	4.0
	Other Meetings	58.0	58.0	116.0
	Disciplinaries	0.0	2.0	2.0
	Examination	48.0	48.0	96.0
	Grading	11.0	11.0	22.0
Carl Benson	Board Meeting	56.0	63.0	119.0
	Committees	3.0	11.0	14.0
	Other Meetings	58.0	58.0	116.0
	Disciplinaries	6.0	6.0	12.0
	Examination	48.0	48.0	96.0
	Grading	11.0	11.5	22.0
Jean Lemberg	Board Meeting	56.0	63.5	119.0
	Committees	0.0	0.0	0.0
	Other Meetings	58.0	58.0	116.0
	Disciplinaries	0.0	0.0	0.0
	Examination	40.0	48.0	88.0
	Grading	11.0	11.5	22.0

Charles Cooper	Board Meeting	0.0	35.0	35.0
	Committees	0.0	0.0	0.0
	Other Meetings	0.0	58.0	58.0
	Disciplinaries	0.0	0.0	0.0
	Examination	0.0	48.0	48.0
	Grading	0.0	11.0	11.0
Jeffery Lindoo	Board Meeting	0.0	35.0	35.0
	Committees	0.0	2.0	2.0
	Other Meetings	0.0	40.0	40.0
	Disciplinaries	0.0	0.0	0.0
	Examination	0.0	24.0	24.0
	Grading	0.0	10.0	10.0

Clause c: **THE RECEIPT AND DISBURSEMENT OF BOARD FUNDS**

	FY 95	FY 96	FY 95 & 96
Total State Appropriations	618,977	700,000	1,318,977
Total Non-Dedicated Fee Receipts	692,654	699,391	1,392,045
Disbursements - direct	611,777	662,306	1,274,083
- indirect	35,141	26,892	62,033
Total Disbursements	646,918	689,198	1,336,116

Clause d: **LIST OF BOARD MEMBERS WHO SERVED DURING FY 95 AND FY 96**

For easy reference please give:

a) Number of Board members required by statute: 7

b) The statutory length of term: 4 years

NAME AND ADDRESS	OCCUPATION	BEGIN AND END DATE OF APPOINTMENT AND EACH REAPPOINTMENT
Carol Peterson Owatonna, MN	Retired	5/91 - 1/95
Denise M. Groehler Milaca, MN	Pharmacist	5/91 - 1/95
Howard A. Juni White Bear Lake, MN	Pharmacist	3/92 - 1/96
Wendy A. Simenson Ramsey, MN	Pharmacist	3/92 - 1/96
Donald Gibson Duluth, MN	Pharmacist	4/93 - 1/97
Carl Benson Morris, MN	Pharmacist	1/94 - 1/98
Jean Lemberg Arden Hills, MN	Retired	1/94 - 1/98
Carol Peterson Owatonna, MN	Retired	1/95 - 1/99
Denise M. Groehler Milaca, MN	Pharmacist	1/95 - 1/99
Charles B. Cooper Eagan, MN	Pharmacist	1/96 - 1/00
Jeffery B. Lindoc Alexandria, MN	Pharmacist	1/96 - 1/00

Clause e: **LIST BOARD EMPLOYEES WHO WERE EMPLOYED DURING FY 95 AND/OR FY 96**

NAME	JOB CLASSIFICATION/ TITLE AND CLASS	CLASS CODE	FT	PT	DATES OF SERVICE
David Holmstrom	Executive Director	OUNC	X		12/29/71 to Present
Lloyd Pekas	Pharmacy Surveyor	1347	X		11/7/77 to Present
Judy Sande	Clerk Typist II	0980	X		10/15/87 to 3/7/95
Patricia Bellino	Pharmacy Surveyor	1347	X		3/16/88 to Present
Stuart Vandenberg	Pharmacy Surveyor	1347	X		4/26/89 to Present
Patricia Eggers	Office Service Supervisor II	0293	X		3/28/90 to Present
E. Kristen Perry	Clerk Typist IV	0666	X		4/11/90 to Present
Julie Kittleson	Clerk Typist III	1929	X		11/4/92 to Present
Leslie Kotek	Pharmacy Surveyor	1347	X		1/13/93 to Present
Shelly A. Gans	Clerk Typist II	0980	X		7/18/95 to 6/28/95
Alicia A. Nordin	Clerk Typist II	0980	X		10/4/95 to Present

Clause f: **BRIEF SUMMARY OF BOARD RULES PROPOSED OR ADOPTED DURING THIS REPORTING PERIOD, FY 95 AND FY 96. GIVE APPROPRIATE CITATIONS TO THE STATE REGISTER AND PUBLISHED RULES FOR THOSE ADOPTED.**

See Attached

Board of Pharmacy

Proposed Permanent Rules Relating to Controlled Substances

Effective 6/10/96

Rules as Proposed

6800.4210 SCHEDULE I CONTROLLED SUBSTANCES.

Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this part.

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers (whether optical, positional, or geometric), esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

[For text of subitems (1) and (2), see M.R.]

(3) Alphacetylmethadol (except levo-alpha-acetylmethadol, also known as levomethadyl Acetate or LAAM);

[For text of subitems (4) to (29), see M.R.]

(30) MPPP~~;~~

~~1-Methyl-4-Phenyl-4-Propionoxypiperidine;~~

~~(31)~~ Methyl substituted isomers of Fentanyl;

(a) 3-Methylfentanyl;
N-[3-Methyl-a-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide

(b) Acetyl-alpha-methylfentanyl;
N-[1-(Methyl-2-phenyl)ethyl-4-piperidyl]-N-phenylacetamide

(c) Alpha-methylthiofentanyl;
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

(d) Benzylfentanyl;
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

(e) Beta-hydroxyfentanyl;
N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide

(f) Beta-hydroxy-3-Methylfentanyl;

Approved by Revisor CMR

N-[3-Methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide

(g) 3-Methylthiofentanyl;

N-[3-Methyl-1-(2-(2-thienyl)ethyl)-4-piperidyl]-N-phenylpropanamide

(h) Thenylfentanyl;

N-[1-(2-thienyl)Methyl-4-piperidyl]-N-phenylpropanamide

(i) Thiofentanyl;

N-[1-(2-(2-thienyl)ethyl)-4-piperidyl]-N-phenylpropanamide

(j) para-fluorofentanyl;

N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamide,

its optical isomers, salts and salts of isomers;

~~(32)~~ (31) Morpheridine;

(32) MPPP;

1-Methyl-4-phenyl-4-Propionoxypiperidine;

[For text of subitems (33) to (36), see M.R.]

(37) PEPAP;

1-(2-Phenylethyl)-4-Phenyl-4-Acetyloxypiperidine;

[For text of subitems (38) to (48), see M.R.]

B. Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine;

(2) Acetyldihydrocodeine;

(3) ~~Acetylcodone;~~

~~(4)~~ Benzylmorphine;

~~(5)~~ (4) Codeine methylbromide;

~~(6)~~ (5) Codeine-N-Oxide;

~~(7)~~ (6) Cyprenorphine;

~~(8)~~ (7) Desomorphine;

~~(9)~~ (8) Dihydromorphine;

~~(10)~~ (9) Drotebanol;

~~(11)~~ (10) Etorphine (except hydrochloride salt);

~~(12)~~ (11) Heroin;

Approved
by Revisor _____

~~(13)~~ (12) Hydromorphinol;

~~(14)~~ (13) Methyldesorphine;

~~(15)~~ (14) Methylhydromorphine/Methyldihydromorphine;

~~(16)~~ (15) Morphine Methylbromide;

~~(17)~~ (16) Morphine Methylsulfonate;

~~(18)~~ (17) Morphine-N-Oxide;

~~(19)~~ (18) Myrophine;

~~(20)~~ (19) Nicocodeine;

~~(21)~~ (20) Nicomorphine;

~~(22)~~ (21) Normorphine;

~~(23)~~ (22) Pholcodine; and

~~(24)~~ (23) Thebacon.

C. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers (whether optical, positional, or geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.

[For text of subitems (1) to (10), see M.R.]

(11) Alpha-Ethyltryptamine	Etryptamine; monase; α-Ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; α-ET; and AET
(12) Bufotenine	3-(b-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine
~~(12)~~ (13) Diethyltryptamine	N,N-Diethyltryptamine; DET
~~(13)~~ (14) Dimethyltryptamine	DMT
~~(14)~~ (15) Ibogaine	7-Ethyl-6,6b,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga
~~(15)~~ (16) Lysergic acid diethylamide	LSD
~~(16)~~ (17) Marijuana	
~~(17)~~ (18) Mescaline	

Approved by Revisor _____

~~(16)~~	(19) Parahexyl	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl
~~(19)~~	(20) Peyote Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or extracts	
~~(20)~~	(21) N-ethyl-3-piperidyl Benzilate	JB-318
~~(21)~~	(22) N-methyl-3-piperidyl Benzilate	JB-336
~~(22)~~	(23) Psilocybin	
~~(23)~~	(24) Psilocyn	
~~(24)~~	(25) Tetrahydrocannabinols Synthetic equivalents of the substances contained in the plant, or in the resinous extractives of cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activities such as the following: 1 cis or trans tetrahydrocannabinol, and their optical isomers, excluding dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration. 6 cis or trans tetrahydrocannabinol, and their optical isomers; 3,4 cis or trans tetrahydrocannabinol, and its optical isomers (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)	THC
~~(25)~~	(26) Ethylamine analog of phencyclidine	N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE
~~(26)~~	(27) Pyrrolidine analog of phencyclidine	1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP
~~(27)~~	(28) Thiophene analog of phencyclidine	1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienyl analog

Approved by Revisor _____

		of phencyclidine, TPCP, TCP
~~(28)~~	(29) 2-thienyl Pyrrolidine analog of Phencyclidine	1-[1-(2-thienyl)cyclohexyl]-pyrrolidine, TCPy

[For text of items D and E, see M.R.]

F. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

	Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1)	Aminorex	Aminoxaphen; 2-Amino-5-phenyl-2-oxazoline; 4,5-Dihydro-5-phenyl-2-oxazolamine
(2)	Cathinone	2-Amino-1-phenyl-1-propanone; alpha-Aminopropiophenone; 2-Aminopropiophenone; Norephedrone
(3)	Fenethylline;	
(4)	Methcathinone	2-(Methylamino)-Propiophenone; alpha-(Methylamino)-propiophenone; 2-(Methylamino)-1-Phenylpropan-1-one; alpha-N-Methylaminopropiophenone; monomethylpropion; ephedrone; N-Methylcathinone; Methylcathinone
~~(2)~~ (5)	4-Methylaminorex(2-Amino-4-methyl-5-phenyl-2-oxazoline);	
~~(3)~~ (6)	N-ethylamphetamine;	
(7)	N,N-dimethylamphetamine	N,N-alpha-trimethly-benzene-ethanamine; N,N-alpha-trimethylphenethylamine

6800.4220 SCHEDULE II CONTROLLED SUBSTANCES.

The following items are listed in Schedule II:

[For text of items A and B, see M.R.]

C. Opiates. Unless specifically excepted or unless listed in another schedule any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

Statutory Name	Some examples of common names, trade names, or names

Approved by Revisor _____

	Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1)	Alfentanil	Alfenta
(2)	Alphaprodine	Nisentil
(3)	Anileridine	Leritine
(4)	Bezitramide	
(5)	Bulk Dextropropoxyphene (nondosage forms)	
(6)	Carfentanil	
(7)	Dihydrocodeine	Paracodin
(8)	Dihydromorphinone	Dilaudid
(9)	Diphenoxylate	
(10)	Fentanyl	Sublimaze, Innovar
(11)	Isomethadone	
(12)	Levo-alpha-acetylmethadol	LAAM
(13)	Levomethorphan	
~~(13)~~ (14)	Levorphanol	Levo-Dromoran
~~(14)~~ (15)	Metazocine	
~~(15)~~ (16)	Methadone	Dolophine, Amidone, Adanon
~~(16)~~ (17)	Methadone-Intermediate 4-cyano-2-dimethylamino-4, 4-diphenylbutane	
~~(17)~~ (18)	Moramide-Intermediate 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid	
~~(18)~~ (19)	Pethidine (meperidine)	Meperidine, Demerol, Isonipecaine, Mepadin, Mepergan
~~(19)~~ (20)	Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine	
~~(20)~~ (21)	Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate	
~~(21)~~ (22)	Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid	
~~(22)~~ (23)	Phenazocine	Prinadol
~~(23)~~ (24)	Piminodine	Alvodine
~~(24)~~ (25)	Racemethorphan	
~~(25)~~ (26)	Racemorphan	Dromoran
~~(26)~~ (27)	Sufentanil	Sufenta

[For text of item D, see M.R.]

E. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

	Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1)	Amobarbital	Amytal
(2)	Glutethimide	Doriden
(3)	Pentobarbital	Nembutal, Tuinal
~~(3)~~	~~Phencyclidine~~	
(4)	Phencyclidine	Sernyl, Sernylar

Approved by Revisor _____

~~(4)~~	~~Secobarbital~~	
(5)	Secobarbital	Seconal

[For text of items F and G, see M.R.]

6800.4230 SCHEDULE III CONTROLLED SUBSTANCES.

The following items are listed in Schedule III:

[For text of items A and B, see M.R.]

C. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance
(1) Any compound, mixture, or preparation containing: (a) Amobarbital; (b) Secobarbital; (c) Pentobarbital, or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.	
(2) Any suppository dosage form containing: (a) Amobarbital; (b) Secobarbital; (c) Pentobarbital, or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.	
(3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically excepted or listed in other schedules:	Butabarbital, Vinbarbital, Delvinal, Talbutal, Lotusate, Pentothal, Brevital
(4) Chlorhexadol	
(5) ~~Glutethimide~~	~~Doriden~~
~~(6)~~ Lysergic acid	
~~(7)~~ (6) Lysergic acid amide	
~~(8)~~ (7) Methyprylon	Noludar
~~(9)~~ (8) Sulfondiethylmethane	
~~(10)~~ (9) Sulfonethylmethane	
~~(11)~~ (10) Sulfonmethane	
(11) Tiletamine and zolazepam and any salt thereof	

[For text of items D to F, see M.R.]

6800.4240 SCHEDULE IV CONTROLLED SUBSTANCES.

Approved by Revisor _____

The following items are listed in Schedule IV:

[For text of items A and B, see M.R.]

C. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.

[For text of subitems (1) to (47), see M.R.]

(48) Zolpidem

[For text of item D, see M.R.]

E. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance
(1) Cathine ((+)-Norpseudoephedrine)	
(2) Diethylpropion	Tenuate, Tepanil
(3) Fencamfamin	
(4) Fenproporex	
~~(2)~~ (5) Mazindol	Sanorex
~~(3)~~ (6) Pemoline (including organometallic complexes and chelates thereof	Cylert
~~(4)~~ (7) Phentermine	Wilpo, Fastin, Ionamin
~~(5)~~ (8) Pipradrol	
~~(6)~~ (9) SPA ((-)-1-dimethylamino-1, 2-diphenylethane)	

[For text of item F, see M.R.]

Approved by Revisor _____

Clause q: **LIST THE NUMBER OF PERSON HAVING EACH TYPE OF LICENSE AND REGISTRATION ISSUED BY THE BOARD AS OF JUNE 30, 1996 (IN THE YEAR OF THE REPORT)**

TYPE OF LICENSE/REGISTRATION	TOTAL NUMBER IN EFFECT
Pharmacist	5,106 Active 71 Inactive 39 Emeritus
Pharmacy	1,227
Drug Wholesaler	567
Drug Manufacturer	252
Drug Researcher	80
Pharmacist-Intern	487
Medical Gas Distributors	27

Clause h: **ADMINISTRATION OF EXAMINATIONS BY BOARD**

LOCATION	TYPES OF LICENSE/REGISTRATION	DATES	TYPE OF EXAM
Sheraton Midway Hotel	Pharmacist/Reciprocity	10/4/94	Written/Oral
Mpls Convention Ctr	Pharmacist/Reciprocity	1/24/95	Written/Oral
Radisson University	Pharmacist/Examination	1/24/95	Written
Radisson University UofM College of Phcy	Pharmacist/Examination	1/25/95	Written Practical
Sheraton Midway/Hotel	Pharmacist/Reciprocity	4/11/95	Written/Oral
Sheraton Midway/Hotel	Pharmacist/Reciprocity	6/27/95	Written/Oral
Mpls Convention Ctr	Pharmacist/Examination	6/27/95	Written
Mpls Convention Ctr	Pharmacist/Examination	6/28/95	Written Practical
Radisson University	Pharmacist/Reciprocity	9/26/95	Written/Oral
Mpls Convention Ctr	Pharmacist/Reciprocity	1/23/96	Written/Oral
Mpls Convention Ctr	Pharmacist/Examination	1/23/96	Written
Mpls Convention Ctr	Pharmacist/Examination	1/24/96	Written Practical
Sheraton Midway Hotel	Pharmacist/Reciprocity	4/10/96	Written/Oral
Sheraton Midway Hotel	Pharmacist/Reciprocity	6/25/96	Written/Oral
Best Western Northwest Inn	Pharmacist/Examination	6/25/96	Written
Best Western Northwest Inn	Pharmacist/Examination	6/25/96	Written Practical

Clauses i, j, k: **MINNESOTA RESIDENTS BY TYPE OF LICENSE/REGISTRATION**

Type of License/Registration: Pharmacist

FY 95

Age Group	Male	Female	Total
18 - 25	23 Passed	29 Passed	52 Passed
	5 Failed	4 Failed	9 Failed
26 - 34	16 Passed	19 Passed	35 Passed
	0 Failed	2 Failed	2 Failed
35 - 59	2 Passed	0 Passed	2 Passed
	0 Failed	0 Failed	0 Failed

FY 96

Age Group	Male	Female	Total
18 - 25	18 Passed	37 Passed	55 Passed
	2 Failed	5 Failed	7 Failed
26 - 34	8 Passed	21 Passed	29 Passed
	0 Failed	1 Failed	1 Failed
35 - 59	0 Passed	5 Passed	5 Passed
	0 Failed	0 Failed	0 Failed

FY 95 & 96

Age Group	Male	Female	Total
18 - 25	41 Passed	66 Passed	107 Passed
	7 Failed	9 Failed	16 Failed
26 - 34	24 Passed	40 Passed	64 Passed
	0 Failed	3 Failed	3 Failed
35 - 59	2 Passed	5 Passed	7 Passed
	0 Failed	0 Failed	0 Failed

Clauses i, j, k: **NON-MINNESOTA RESIDENTS BY TYPE OF LICENSE/REGISTRATION**

Type of License/Registration: Pharmacist

FY 95

Age Group	Male	Female	Total
18 - 25	15 Passed	25 Passed	40 Passed
	8 Failed	6 Failed	14 Failed
26 - 34	19 Passed	18 Passed	37 Passed
	4 Failed	0 Failed	4 Failed
35 - 59	12 Passed	9 Passed	21 Passed
	4 Failed	0 Failed	4 Failed

FY 96

Age Group	Male	Female	Total
18 - 25	14 Passed	34 Passed	48 Passed
	0 Failed	3 Failed	3 Failed
26 - 34	20 Passed	32 Passed	52 Passed
	6 Failed	5 Failed	11 Failed
35 - 59	18 Passed	12 Passed	30 Passed
	3 Failed	3 Failed	6 Failed
60 - 75	1 Passed	0 Passed	1 Passed
	0 Failed	0 Failed	0 Failed

FY 95 & 96

Age Group	Male	Female	Total
18 - 25	29 Passed	59 Passed	88 Passed
	8 Failed	9 Failed	17 Failed
26 - 34	39 Passed	50 Passed	89 Passed
	10 Failed	5 Failed	15 Failed
35 - 59	30 Passed	21 Passed	51 Passed
	7 Failed	3 Failed	10 Failed
60 - 75	1 Passed	0 Passed	1 Passed
	0 Failed	0 Failed	0 Failed

Total number of non-residents by state

FY 95:

STATE	MALE PASSED	MALE FAILED	FEMALE PASSED	FEMALE FAILED	TOTAL PASSED	TOTAL FAILED
AL	0	0	0	0	0	0
AK	0	0	0	0	0	0
AZ	5	0	1	0	6	0
AR	1	0	0	0	1	0
CA	0	0	0	0	0	0
CO	0	0	0	0	0	0
CT	2	0	0	0	2	0
DE	0	0	0	0	0	0
FL	0	0	2	0	2	0
GA	0	0	0	0	0	0
HI	0	0	0	0	0	0
ID	1	0	1	0	2	0
IL	1	0	2	2	3	2
IN	0	3	3	1	3	4
IA	8	2	6	1	14	3
KS	0	0	1	0	1	0
KY	0	0	0	0	0	0
LA	0	0	0	0	0	0
ME	0	1	0	0	0	1
MD	0	0	1	0	1	0
MA	0	0	0	0	0	0
MI	0	0	4	1	4	1
MN	0	0	0	0	0	0
MS	1	0	0	0	1	0
MO	0	0	0	0	0	0
MT	2	0	0	0	2	0
NE	2	0	4	0	6	0
NV	1	0	2	0	3	0
NH	0	0	0	0	0	0
NJ	1	0	2	0	3	0
NM	1	2	1	0	2	2
NY	0	0	3	0	3	0
NC	0	1	0	0	0	1
ND	8	3	9	4	17	7
OH	0	0	0	0	0	0
OK	0	0	0	0	0	0
OR	2	1	1	0	3	1
PA	0	0	0	0	0	0
RI	0	0	0	0	0	0
SC	0	0	0	0	0	0
SD	6	1	9	2	15	3
TN	0	0	0	0	0	0
TX	0	0	1	1	1	1
UT	1	0	1	0	2	0
VA	0	0	0	0	0	0
WA	0	0	0	0	0	0
WV	0	0	0	0	0	0
WI	5	1	6	1	11	2
WY	0	0	0	0	0	0
Foreign	1	1	3	2	4	3

FY 96:

STATE	MALE		FEMALE		TOTAL	
	PASSED	FAILED	PASSED	FAILED	PASSED	FAILED
AL	0	0	0	1	0	1
AK	0	0	0	0	0	0
AZ	1	0	1	0	2	0
AR	0	0	0	0	0	0
CA	0	0	1	0	1	0
CO	2	0	2	0	4	0
CT	1	1	1	0	2	1
DE	0	0	0	0	0	0
FL	0	0	1	0	1	0
GA	1	1	0	0	2	0
HI	0	0	0	0	0	0
ID	0	0	0	0	0	0
IL	5	0	4	1	9	1
IN	2	0	1	1	3	1
IA	11	3	9	0	20	3
KS	0	0	1	0	1	0
KY	0	0	0	0	0	0
LA	0	0	0	0	0	0
ME	0	0	1	0	1	0
MD	0	0	0	0	0	0
MA	2	0	0	0	2	0
MI	2	0	3	1	5	1
MN	0	0	0	0	0	0
MS	1	0	0	0	1	0
MO	0	0	0	0	0	0
MT	0	0	0	0	0	0
NE	0	1	2	0	2	1
NV	1	0	0	0	1	0
NH	1	1	0	0	1	1
NJ	1	1	1	0	2	1
NM	1	0	1	2	2	2
NY	1	1	1	0	2	1
NC	0	0	0	0	0	0
ND	11	0	17	4	28	4
OH	1	1	3	0	4	1
OK	2	0	0	0	2	0
OR	0	0	1	0	1	0
PA	0	0	2	1	2	1
RI	0	0	1	0	1	0
SC	0	0	0	0	0	0
SD	3	0	7	0	10	0
TN	0	0	0	1	0	1
TX	3	0	2	0	5	2
UT	0	0	0	0	0	0
VA	1	0	0	0	1	0
WA	0	0	1	0	1	0
WV	0	0	1	0	1	0
WI	5	1	3	3	8	4
WY	0	0	1	0	1	0
Foreign	0	0	2	0	2	0

FY 95 & 96:

STATE	MALE PASSED	MALE FAILED	FEMALE PASSED	FEMALE FAILED	TOTAL PASSED	TOTAL FAILED
AL	0	0	0	1	0	1
AK	0	0	0	0	0	0
AZ	6	0	2	0	8	0
AR	1	0	0	0	1	0
CA	0	0	1	0	1	0
CO	2	0	2	0	4	0
CT	3	1	1	0	4	1
DE	0	0	0	0	0	0
FL	0	0	3	0	3	0
GA	1	1	0	0	2	0
HI	0	0	0	0	0	0
ID	1	0	1	0	2	0
IL	6	0	6	3	12	3
IN	2	3	4	2	6	5
IA	19	5	15	1	34	6
KS	0	0	2	0	2	0
KY	0	0	0	0	0	0
LA	0	0	0	0	0	0
ME	0	1	1	0	1	1
MD	0	0	1	0	1	0
MA	2	0	0	0	2	0
MI	2	0	7	2	9	2
MN	0	0	0	0	0	0
MS	2	0	0	0	2	0
MO	0	0	0	0	0	0
MT	2	0	0	0	2	0
NE	2	1	6	0	8	1
NV	2	0	2	0	4	0
NH	1	1	0	0	1	1
NJ	2	1	3	0	5	1
NM	2	2	2	0	4	2
NY	1	1	4	0	5	1
NC	0	1	0	0	0	1
ND	19	3	26	8	45	11
OH	1	1	3	0	4	1
OK	2	0	0	0	2	0
OR	2	1	2	0	4	1
PA	0	0	2	1	2	1
RI	0	0	1	0	1	0
SC	0	0	0	0	0	0
SD	9	1	16	2	25	3
TN	0	0	0	1	0	1
TX	3	0	3	1	6	1
UT	1	0	1	0	2	0
VA	1	0	0	0	1	0
WA	0	0	1	0	1	0
WV	0	0	1	0	1	0
WI	10	2	9	4	19	6
WY	0	0	1	0	1	0
Foreign	1	1	5	2	6	3

Clause 1: **THE NUMBER OF PERSONS NOT TAKING EXAMINATIONS WHO WERE LICENSED OR REGISTERED BY THE BOARD OR WHO WERE DENIED LICENSING OR REGISTRATION WITH THE REASONS FOR THE LICENSING OR REGISTRATION OR DENIAL THEREOF.**

T al number of persons not taking exams and granted licenses or registration:

FY 95 = None
FY 96 = None
FY 95 & 96 = None

Total number of persons not taking exams and denied licenses or registration:

FY 95 = None
FY 96 = None
FY 95 & 96 = None

Clause m: **PERSONS PREVIOUSLY LICENSED OR REGISTERED BY THE BOARD WHOSE LICENSES OR REGISTRATIONS WERE REVOKED, SUSPENDED OR OTHERWISE ALTERED IN STATUS, WITH BRIEF STATEMENTS OF THE REASONS FOR THE REVOCATION, SUSPENSION OR ALTERATIONS.**

	FY 95	FY 96	FY 95 & 96
TOTAL number of revocations	111	51	162
TOTAL number of suspensions	2	1	3
TOTAL number of other status changes	16	15	31

Type of license or registration: All cases involved pharmacists.

TYPE OF STATUS CHANGE			
REVOKED	SUSPENDED	OTHER (SPECIFY)	REASON FOR CHANGE
162			Non-payment of Fees
	2		Chemical Dependency/Theft
	1		Probation Violation
		3 Probation	Violation of Federal laws
		1 Probation	Probation Violation
		1 Probation	Unprofessional Conduct
		1 Probation	Unprofessional Conduct/ Drug Diversion
		6 Probation	Chemical Dependency
		1 Probation	Chemical Dependency Theft
		1 Probation	Practicing Pharmacy with No License
		1 Probation	Incompetence
		1 Probation	Theft
		1 Probation	Unsanitary Conditions in Pharmacy
		9 Off Probation	Chemical Dependency
		1 Off Probation	Allowing Unlicensed RPh in Pharmacy
		1 Off Probation	Theft
		1 Off Probation	Insurance Fraud in Arizona
		1 Off Probation	Unprofessional Conduct/ Poor Recordkeeping
		1 Off Probation	Medicaid Fraud

Clause n: **LIST THE NUMBER OF COMPLAINTS AND OTHER COMMUNICATIONS RECEIVED BY THE EXECUTIVE DIRECTOR, EACH BOARD MEMBER, EMPLOYEE OR OTHER PERSON PERFORMING SERVICES FOR THE BOARD**

That allege or imply a violation of a statute or rule which the Board is empowered to enforce. These totals include cases referred to the attorney general's staff who are assigned to assist your board.

	FY 95	FY 96
Written	79	90
Oral	0	0

Which are forwarded to other agencies as required by M.S. 214.10.

	FY 95	FY 96
Written	2	3
Oral	0	0

Please indicate the number of complaints referred to each other governmental agency (federal, state and local) in each fiscal year:

	FY 95	FY 96
Medical Board	2	3
Nursing Board	0	1
Veterinary Board	2	1
DHS	1	1
FDA	0	1
HPSP	0	1
AG's Office	0	1

Clause o: **SUMMARIZE, BY SPECIFIC CATEGORY, THE SUBSTANCE OF THE COMPLAINTS AND COMMUNICATIONS REFERRED TO IN CLAUSE (N) OF M.S. 214.07 AND, FOR EACH SPECIFIC CATEGORY, THE RESPONSES OR DISPOSITIONS THEREOF PURSUANT TO M.S. 214.10 AND 214.11 (INDICATE AUTHORITY/CITATIONS FOR DISPOSITION).**

SUMMARY OF COMPLAINTS AND COMMUNICATIONS.

77 Prescription errors all complaints investigated, no disciplinary action taken. All pharmacists were subject to educational sessions as per 214.10.

9 Unprofessional Conduct	Dismissed (214.10)
3 Pricing Issues	Dismissed (214.10)
7 Labeling errors	Dismissed (214.10)
4 Billing errors	Dismissed (214.10)
3 Chemical Dependency	Dismissed (214.10)
6 Outdated Drugs	Dismissed (214.10)
8 Unauthorized Refills	Dismissed (214.10)
4 Improper Use of Supportive Personnel	Dismissed (214.10)
1 Fraud	Dismissed (214.10)
1 Pharmacist Provided Inadequate Service To Hospital	Dismissed (214.10)
14 Miscellaneous	Dismissed (214.10)
12 Using Generic without Patient Approval	Dismissed (214.10)
1 Privacy Issue	Dismissed (214.10)
1 Patient Waited too Long	Dismissed (214.10)
2 Pharmacist Absent When Phcy Open	Dismissed (214.10)
4 Failure to Counsel	Dismissed (214.10)
2 Refusal to Give Copies	Dismissed (214.10)
2 Pharmacist Failed to Detect Overdose	Dismissed (214.10)
2 Kickback	Dismissed (214.10)
2 Inadequate DUR	Dismissed (214.10)
3 Pharmacist Refused to Fill RX	Dismissed (214.10)
1 Manufacture & Promotion of Drug Without NDA	Dismissed (214.10)

Clause D: STATE ANY OTHER OBJECTIVE INFORMATION WHICH THE BOARD MEMBERS BELIEVE WILL BE USEFUL IN REVIEWING BOARD ACTIVITIES.

Many warning letters (over 100) were written and several formal disciplinary actions took place as a result of inspections by our staff.

1. An informal, but yet effective, sharing of information is in effect between the health licensing boards. With all health licensing boards located in the same building, communication is continually on-going.

2. Minnesota Board of Pharmacy participates in a national disciplinary clearing house mediated through the National Association of Boards of Pharmacy.

Item g: FOR ALL HEALTH RELATED BOARDS, EXCEPT THE BOARD OF VETERINARY MEDICINE, PER M.S. 1985 SUPPLEMENT, SECTION 214.10, SUBD. 8(B): PROVIDE A SUMMARY OF EACH INDIVIDUAL CASE (COMPLAINT OR OTHER COMMUNICATION) THAT INVOLVED POSSIBLE SEXUAL CONTACT OF A LICENSEE WITH A PATIENT OR CLIENT

None.